In the European Union, even minor formulation changes in pharmaceuticals can lead to a complex web of national regulatory filings, differing interpretations, and extensive administrative hurdles. Companies must approach these changes strategically, anticipating variations and managing multiple timelines. This landscape demands foresight, organization, and collaboration across departments. The article discusses ways to improve the process, emphasizing the need for regulatory intelligence, integrated planning, and digital tracking to navigate the intricate regulatory environment effectively.
